Last reviewed · How we verify
TGR-1202
TGR-1202 is a selective inhibitor of the PI3K delta subunit.
TGR-1202 is a selective inhibitor of the PI3K delta subunit. Used for Relapsed or refractory B-cell malignancies.
At a glance
| Generic name | TGR-1202 |
|---|---|
| Also known as | formerly as RP5307, RP5264, Umbralisib, umbralisib, (formerly) RP-5264 |
| Sponsor | Vanderbilt-Ingram Cancer Center |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting PI3K delta, TGR-1202 disrupts the signaling pathways that promote the survival and proliferation of cancer cells. This leads to the induction of apoptosis and inhibition of tumor growth. Additionally, TGR-1202 has been shown to enhance the anti-tumor activity of other therapies.
Approved indications
- Relapsed or refractory B-cell malignancies
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (PHASE2)
- Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma (PHASE2)
- TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) (PHASE2)
- Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL (PHASE1)
- Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (PHASE3)
- Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma (PHASE2)
- A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL (PHASE1)
- Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TGR-1202 CI brief — competitive landscape report
- TGR-1202 updates RSS · CI watch RSS
- Vanderbilt-Ingram Cancer Center portfolio CI